Cargando…
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. They also reduce body we...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474213/ https://www.ncbi.nlm.nih.gov/pubmed/37209227 http://dx.doi.org/10.1007/s00125-023-05929-0 |